Immune Thrombocytopenia Induced by Sintilimab in Lung Cancer: 
A Case Report and Literature Review

Immune checkpoint inhibitors (ICIs) show unique advantages in the treatment of lung cancer, making the treatment of lung cancer enter the era of immunotherapy, but ICIs will also have adverse reactions, and the incidence of immune-induced hematological toxicity is not very high. Immunotherapy-induce...

Full description

Bibliographic Details

Published in:	Chinese Journal of Lung Cancer
Main Authors:	Jingjing CAI, Guangxia YANG, Xuemei ZHANG, Linlin LIU, Mei YAN
Format:	Article
Language:	Chinese
Published:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2023-09-01
Subjects:	immune checkpoint inhibitors sintilimab injection immune thrombocytopenia lung neoplasms immune-related adverse events
Online Access:	http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.32